GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Letrozole

Company
Xiaojun Chen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
78 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

78 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Letrozole and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01042379

    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    Not yet reported QuantumLeap Healthcare Collaborative 5000 participants Est. completion 2031-12 42 sites Stand-alone
    Obstructive sleep apnea Other conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT02476786

    Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

    Not yet reported Washington University School of Medicine 50 participants Est. completion 2032-07-31 1 site Stand-alone
    Other conditions: Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
    View official trial listing →
  • Recruiting NCT NCT03424005

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 1132 participants Est. completion 2030-09-30 53 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT03458221

    Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

    Not yet reported, Not yet reported Gynaecologisch Oncologisch Centrum Zuid 148 participants Est. completion 2026-10-01 6 sites Stand-alone
    Other conditions: Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer
    View official trial listing →
  • Recruiting NCT NCT03624244

    Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

    Not yet reported Centre Leon Berard 40 participants Est. completion 2031-01 22 sites
    Other conditions: Low Grade Endometrial Stromal Sarcoma
    View official trial listing →
  • Recruiting NCT NCT03675893

    RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer

    Not yet reported Dana-Farber Cancer Institute 110 participants Est. completion 2031-08-01 3 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT04111978

    MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

    Not yet reported Swiss GO Trial Group 540 participants Est. completion 2032-07-01 53 sites Stand-alone
    Other conditions: Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma
    View official trial listing →
  • Recruiting NCT NCT04166825

    Ovarian Hyperstimulation and Fibrin Clot Properties.

    Not yet reported Jagiellonian University 300 participants Est. completion 2026-01 1 site
    Other conditions: Fibrin Blood Clot, Infertility, Female, Endometriosis
    View official trial listing →
  • Recruiting NCT NCT04476485

    Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

    Shengjing Hospital 1000 participants Est. completion 2026-12-31 12 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04486352

    A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

    Not yet reported, Not yet reported Alliance Foundation Trials, LLC. 148 participants Est. completion 2027-10 21 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT04606446

    Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    Not yet reported Pfizer 320 participants Est. completion 2029-08-10 44 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT04886531

    Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

    Not yet reported Ruth O'Regan 30 participants Est. completion 2027-12-21 4 sites Stand-alone
    Other conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05035836

    A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

    Not yet reported M.D. Anderson Cancer Center 20 participants Est. completion 2028-12-29 1 site Stand-alone
    Other conditions: Breast Cancer, HER2-positive
    View official trial listing →
  • Recruiting NCT NCT05190094

    Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

    Not yet reported International Cancer Research Group, United Arab Emirates 80 participants Est. completion 2026-06 7 sites Stand-alone
    Other conditions: Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05247268

    Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

    Not yet reported Fudan University 104 participants Est. completion 2027-09-10 1 site Stand-alone
    Other conditions: Endometrial Neoplasm Malignant Stage I
    View official trial listing →
  • Recruiting NCT NCT05297617

    Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

    Not yet reported UNICANCER 696 participants Est. completion 2035-11 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05316935

    GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

    Not yet reported, Not yet reported Xiaojun Chen 80 participants Est. completion 2028-03-30 2 sites Stand-alone
    Other conditions: Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
    View official trial listing →
  • Recruiting NCT NCT05341817

    The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy

    Not yet reported KK Women's and Children's Hospital 144 participants Est. completion 2025-11 1 site Stand-alone
    Other conditions: Abortion in First Trimester
    View official trial listing →
  • Recruiting NCT NCT05362760

    Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

    Not yet reported Prof. Wolfgang Janni 300 participants Est. completion 2029-04 54 sites Stand-alone
    Other conditions: Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05464810

    Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

    Not yet reported Emory University 40 participants Est. completion 2028-04-15 4 sites Stand-alone
    Other conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05487092

    Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy

    Not yet reported The University of Hong Kong 194 participants Est. completion 2027-06-30 5 sites Stand-alone
    Other conditions: Endometriotic Cyst of Ovary
    View official trial listing →
  • Recruiting NCT NCT05512364

    Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 220 participants Est. completion 2035-11-01 111 sites
    Other conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05582499

    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

    Not yet reported Fudan University 716 participants Est. completion 2029-09 1 site Stand-alone
    Other conditions: Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05638594

    Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

    Not yet reported Shengjing Hospital 236 participants Est. completion 2027-12-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05744687

    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

    Not yet reported, Not yet reported Shanghai Pharmaceuticals Holding Co., Ltd 374 participants Est. completion 2026-05-31 9 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05766410

    A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

    Not yet reported National Taiwan University Hospital 60 participants Est. completion 2026-09-30 2 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
    View official trial listing →
  • Recruiting NCT NCT05768139

    First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Eli Lilly and Company 880 participants Est. completion 2030-07 65 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumors, Adult
    View official trial listing →
  • Recruiting NCT NCT05827081

    Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

    Not yet reported Novartis Pharmaceuticals 1400 participants Est. completion 2030-09-20 229 sites Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05837455

    NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

    Not yet reported Washington University School of Medicine 81 participants Est. completion 2027-11-30 1 site Stand-alone
    Other conditions: Breast Cancer, Cancer of the Breast
    View official trial listing →
  • Recruiting NCT NCT05860465

    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported Shanghai Pharmaceuticals Holding Co., Ltd 254 participants Est. completion 2026-12-30 22 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05861271

    Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

    Not yet reported Fudan University 1008 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: Breast Cancer Stage I
    View official trial listing →
  • Recruiting NCT NCT05872347

    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

    Not yet reported Shanghai Pharmaceuticals Holding Co., Ltd 52 participants Est. completion 2026-12-31 25 sites Stand-alone
    Other conditions: Breast Cancer Brain Metastases
    View official trial listing →
  • Recruiting NCT NCT05890287

    A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 60 participants Est. completion 2026-10-01 1 site Stand-alone
    Other conditions: HR Positive HER2 Negative Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05891093

    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

    Not yet reported Fudan University 766 participants Est. completion 2031-05-31 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05894239

    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Not yet reported Hoffmann-La Roche 230 participants Est. completion 2032-12-28 192 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05949541

    Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

    Not yet reported Fudan University 265 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05997017

    Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

    Not yet reported Aadi Bioscience, Inc. 29 participants Est. completion 2027-06 9 sites Stand-alone
    Other conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT06127979

    A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

    Not yet reported Memorial Sloan Kettering Cancer Center 42 participants Est. completion 2028-11 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06139107

    RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

    Not yet reported Mridula George, MD 15 participants Est. completion 2032-09-30 4 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06149130

    Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

    Not yet reported Tongji Hospital 82 participants Est. completion 2026-11-30 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06235931

    A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC

    Not yet reported Second Affiliated Hospital of Soochow University 34 participants Est. completion 2026-12-01 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Recruiting NCT NCT06239376

    Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients

    Not yet reported Mỹ Đức Hospital 222 participants Est. completion 2027-05-30 1 site
    Other conditions: Adenomyosis, IVF, Frozen Embryo Transfer
    View official trial listing →
  • Recruiting NCT NCT06348134

    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

    Not yet reported University of Chicago 74 participants Est. completion 2036-07-01 4 sites Stand-alone
    Other conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06354439

    Use of Letrozole for Ectopic Pregnancy

    Not yet reported Hospital de Clinicas de Porto Alegre 130 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Ectopic Pregnancy
    View official trial listing →
  • Recruiting NCT NCT06372119

    Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)

    Not yet reported Mỹ Đức Hospital 790 participants Est. completion 2026-04 2 sites
    Other conditions: Embryo Transfer, Irregular Menstruation, Letrozole, Hormone Replacement Therapy
    View official trial listing →
  • Recruiting NCT NCT06379113

    GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

    Not yet reported, Not yet reported Xiaojun Chen 29 participants Est. completion 2028-03-30 2 sites Stand-alone
    Other conditions: Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
    View official trial listing →
  • Recruiting NCT NCT06380751

    Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    Not yet reported AstraZeneca 788 participants Est. completion 2031-12-30 306 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06492616

    A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    Not yet reported Stemline Therapeutics, Inc. 4220 participants Est. completion 2032-10 562 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06656624

    Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 190 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06757634

    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    Not yet reported Celcuity Inc 1180 participants Est. completion 2033-07-30 203 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06790693

    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    Not yet reported Hoffmann-La Roche 450 participants Est. completion 2032-02-01 241 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06793904

    Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS

    Not yet reported Cairo University 122 participants Est. completion 2026-01 1 site Stand-alone
    Other conditions: Polycystic Ovarian Syndrome (PCOS)
    View official trial listing →
  • Recruiting NCT NCT06934785

    LE + CC vs. LE for Ovulation Induction

    Not yet reported Mỹ Đức Hospital 600 participants Est. completion 2027-06-30 1 site
    Other conditions: Letrozole, Clomiphene Citrate, Ovulation Disorder, Ovulation Induction
    View official trial listing →
  • Recruiting NCT NCT06970912

    ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

    Not yet reported Peking University People's Hospital 393 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer, ctDNA Monitoring, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
    View official trial listing →
  • Recruiting NCT NCT06979596

    A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

    Not yet reported Merck Sharp & Dohme LLC 250 participants Est. completion 2027-11-04 59 sites Stand-alone
    Other conditions: Malignant Neoplasm
    View official trial listing →
  • Recruiting NCT NCT07019363

    CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

    Not yet reported Fudan University 1903 participants Est. completion 2033-04-15 1 site
    Other conditions: Breast Cancer, Adjuvant Therapy
    View official trial listing →
  • Recruiting NCT NCT07029399

    A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    Not yet reported NiKang Therapeutics, Inc. 361 participants Est. completion 2027-12-31 18 sites Stand-alone
    Other conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07071038

    Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

    Not yet reported Dartmouth-Hitchcock Medical Center 62 participants Est. completion 2027-08-05 1 site
    Other conditions: Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07109947

    Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage

    Not yet reported Aswan University 70 participants Est. completion 2025-12-10 1 site
    Other conditions: Miscarriage
    View official trial listing →
  • Recruiting NCT NCT07159880

    Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)

    Not yet reported GABRIEL MONTEIRO PINHEIRO 20 participants Est. completion 2026-07-30 1 site Stand-alone
    Other conditions: PCOS (Polycystic Ovary Syndrome), Infertility, Anovulation
    View official trial listing →
  • Recruiting NCT NCT07160855

    Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage

    Not yet reported Nishtar Medical University 92 participants Est. completion 2025-11-12 1 site Stand-alone
    Other conditions: Miscarriage in First Trimester, Missed Miscarriage
    View official trial listing →
  • Recruiting NCT NCT07180160

    Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

    Not yet reported Wenjin Yin 123 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07255911

    Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS

    Not yet reported Mst.Sumyara Khatun 72 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: PCOS
    View official trial listing →
  • Recruiting NCT NCT07285382

    Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

    Not yet reported wanghaibo 120 participants Est. completion 2028-12-31 2 sites Stand-alone
    Other conditions: HR Positive HER2 Negative Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07319429

    Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification

    Not yet reported, Not yet reported Fudan University 260 participants Est. completion 2029-12-31 2 sites Stand-alone
    Other conditions: Endometrial Cancer, Fertility
    View official trial listing →
  • Recruiting NCT NCT07380646

    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 94 participants Est. completion 2028-06-01 1 site Stand-alone
    Other conditions: Leucogen, Ribociclib, Neutropenia (Low White Blood Cell Count), Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07389733

    A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

    Not yet reported, Not yet reported Shandong Suncadia Medicine Co., Ltd. 180 participants Est. completion 2028-12 2 sites Stand-alone
    Other conditions: Advanced Unresectable or Metastatic Breast Cancer of Adults
    View official trial listing →
  • Recruiting NCT NCT07391774

    Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    Not yet reported National Cancer Institute (NCI) 1978 participants Est. completion 2029-07-31 175 sites Stand-alone
    Other conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07401381

    A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

    Not yet reported Rovi Pharmaceuticals Laboratories 120 participants Est. completion 2028-10 1 site Stand-alone
    Other conditions: Hormone Receptor Positive Early Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07483307

    A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 176 participants Est. completion 2030-03-13 7 sites Stand-alone
    Other conditions: Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07492641

    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    Not yet reported BeOne Medicines 1056 participants Est. completion 2037-08-07 108 sites Stand-alone
    Other conditions: HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07581834

    Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

    Not yet reported Fujian Cancer Hospital 2000 participants Est. completion 2032-06-30 2 sites Stand-alone
    Other conditions: Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07604571

    Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

    Not yet reported Novartis Pharmaceuticals 194 participants Est. completion 2032-06-08 6 sites Stand-alone
    Other conditions: Advanced HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07610720

    Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

    Not yet reported Sun Yat-sen University 57 participants Est. completion 2029-11-01 1 site Stand-alone
    Other conditions: Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07616427

    Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 100 participants Est. completion 2033-05-20 3 sites Stand-alone
    Other conditions: HR+/HER2+ Early Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07616453

    Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 45 participants Est. completion 2033-05-05 1 site Stand-alone
    Other conditions: HR+/HER2- Early Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07661927

    Skipping Hormone Therapy in Low-Risk Early Breast Cancer

    Not yet reported UNICANCER 700 participants Est. completion 2033-07-06 41 sites Stand-alone
    Other conditions: Breast Cancer (Early Breast Cancer)
    View official trial listing →
  • Recruiting NCT NCT07737951

    Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

    Not yet reported Thomas Jefferson University 40 participants Est. completion 2029-06 1 site
    Other conditions: Hormone Receptor Positive Breast Carcinoma, Postmenopausal, Breast Cancer
    View official trial listing →
  • Completed NCT NCT00003140

    Letrozole After Tamoxifen in Treating Women With Breast Cancer

    Not yet reported NCIC Clinical Trials Group 5187 participants Est. completion 2003-10 57 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00004205

    Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

    Not yet reported ETOP IBCSG Partners Foundation 8028 participants Est. completion 2016-06-30 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00014638

    Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

    Not yet reported Novartis Est. completion 2002-03 20 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00044291

    Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

    Not yet reported Intarcia Therapeutics 865 participants Est. completion 2006-01 63 sites
    Other conditions: Breast Neoplasms, Neoplasms, Hormone-dependent
    View official trial listing →
  • Completed NCT NCT00066339

    Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 44 participants 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00090857

    Letrozole in Preventing Breast Cancer in Postmenopausal Women

    Not yet reported Dana-Farber Cancer Institute 49 participants Est. completion 2013-03 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00097344

    The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

    Not yet reported Intarcia Therapeutics 842 participants Est. completion 2006-08 104 sites
    Other conditions: Breast Neoplasms, Neoplasms, Hormone-Dependent
    View official trial listing →
  • Terminated NCT NCT00101062

    Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

    Not yet reported University of Medicine and Dentistry of New Jersey Est. completion 2005-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00111241

    Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors

    Monash University 115 participants Est. completion 2011-12 1 site
    Other conditions: Arthralgia
    View official trial listing →
  • Completed NCT NCT00134680

    Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

    Not yet reported Duke University 33 participants Est. completion 2005-07 4 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00138710

    Short-term Effects of Aromatase Inhibition in Obese Men

    Not yet reported Rijnstate Hospital 50 participants Est. completion 2010-01 1 site
    Other conditions: Hypogonadotrophic Hypogonadism, Obesity
    View official trial listing →
  • Completed NCT NCT00171340

    Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

    Not yet reported Novartis Pharmaceuticals 1065 participants Est. completion 2010-02 106 sites Stand-alone
    Other conditions: Bone Loss, Breast Cancer
    View official trial listing →
  • Completed NCT NCT00171808

    Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer

    Not yet reported Novartis Pharmaceuticals 26 participants 15 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Terminated NCT NCT00171847

    Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 93 participants 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00208273

    Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer

    Not yet reported Institut du Cancer de Montpellier - Val d'Aurelle 150 participants Est. completion 2007-02 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00237133

    Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

    Not yet reported Novartis Pharmaceuticals 112 participants Est. completion 2009-01-21 11 sites Stand-alone
    Other conditions: Locally Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00237198

    Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

    Not yet reported Novartis Pharmaceuticals 47 participants 24 sites Stand-alone
    Other conditions: Postmenopausal Women With Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00238290

    Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

    Not yet reported Swiss Cancer Institute 13 participants Est. completion 2011-04 14 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00238316

    Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

    Not yet reported NCIC Clinical Trials Group 68 participants Est. completion 2009-02-10 10 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00240071

    Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

    Not yet reported University of Alabama at Birmingham 30 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00248170

    Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

    Not yet reported Novartis Pharmaceuticals 4172 participants Est. completion 2014-09 259 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00263198

    PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer

    Not yet reported Washington University School of Medicine 4 participants Est. completion 2006-11 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00291135

    Protocol for Women at Increased Risk of Developing Breast Cancer

    Not yet reported Carol Fabian, MD 42 participants Est. completion 2008-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00310180

    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

    Not yet reported National Cancer Institute (NCI) 10273 participants Est. completion 2030-09-30 1222 sites Stand-alone
    Other conditions: Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT00333047

    Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

    Not yet reported, Not yet reported Novartis 24 participants 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00333086

    A Study of Letrozole in the Treatment of Endometrial Cancer

    Not yet reported Novartis Pharmaceuticals 36 participants 1 site
    Other conditions: Recurrent and Metastatic Endometrial Cancer
    View official trial listing →
  • Status unknown NCT NCT00351416

    Letrozole Treatment in Normal and GnRH Deficient Women

    Not yet reported, Not yet reported Massachusetts General Hospital 15 participants 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT00369850

    Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

    Not yet reported ETOP IBCSG Partners Foundation 458 participants Est. completion 2012-01 16 sites Stand-alone
    Other conditions: Breast Cancer, Osteoporosis
    View official trial listing →
  • Terminated NCT NCT00375752

    Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

    Not yet reported Novartis Pharmaceuticals 168 participants Est. completion 2010-12-16 27 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00376740

    Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole

    Not yet reported Soroka University Medical Center 90 participants 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00412022

    HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.

    Not yet reported National Cancer Institute, Naples 1294 participants Est. completion 2024-11 20 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00422903

    Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

    Not yet reported GlaxoSmithKline 92 participants Est. completion 2011-04 14 sites Stand-alone
    Other conditions: Neoplasms, Breast
    View official trial listing →
  • Completed NCT NCT00433589

    Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 6600 participants Est. completion 2020-03 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00436917

    Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

    Not yet reported Mayo Clinic 60 participants Est. completion 2016-05-09 2 sites Stand-alone
    Other conditions: Breast Cancer, Osteoporosis
    View official trial listing →
  • Terminated NCT NCT00461773

    Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

    Not yet reported Yale University 5 participants Est. completion 2010-05 1 site
    Other conditions: Hormone-Sensitive Breast Cancer, Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00498901

    Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

    Not yet reported University of Washington 1 participants Est. completion 2008-11 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00504699

    Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

    Not yet reported New York Medical College 120 participants Est. completion 2018-03-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00516542

    Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

    Not yet reported OHSU Knight Cancer Institute 6 participants Est. completion 2010-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00530868

    Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

    Not yet reported University of Alabama at Birmingham 75 participants Est. completion 2022-03-31 7 sites Stand-alone
    Other conditions: Breast Cancer, Cancer of the Breast, Breast Neoplasm
    View official trial listing →
  • Completed NCT NCT00532272

    Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC

    Not yet reported National Cancer Center, Korea 78 participants Est. completion 2010-08 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00535418

    Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

    Not yet reported, Not yet reported Novartis Pharmaceuticals 35 participants Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00541086

    Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

    Not yet reported Gruppo Italiano Mammella (GIM) 3697 participants Est. completion 2020-07 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00545077

    Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

    Not yet reported Spanish Breast Cancer Research Group 380 participants Est. completion 2014-07-24 70 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00549822

    Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

    Not yet reported Massachusetts General Hospital 3 participants Est. completion 2013-09 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00573755

    Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

    Not yet reported Mayo Clinic 4 participants Est. completion 2013-04 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00579826

    Study of Breast Cancer Prevention by Letrozole in High Risk Women

    Not yet reported Carol Fabian, MD 55 participants Est. completion 2018-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00610077

    Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility

    Not yet reported Sun Pharmaceutical Industries Limited 55 participants Est. completion 2006-07 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Terminated NCT NCT00611715

    Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

    Not yet reported Vanderbilt-Ingram Cancer Center 48 participants Est. completion 2008-12 9 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00617968

    GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer

    Not yet reported Sanofi 5 participants Est. completion 2005-06 1 site
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT00634634

    Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

    Not yet reported, Not yet reported Rutgers, The State University of New Jersey 52 participants Est. completion 2023-04-28 4 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00641303

    Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

    Not yet reported University of Maryland, Baltimore 51 participants Est. completion 2011-11 2 sites
    Other conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
    View official trial listing →
  • Completed NCT NCT00648063

    Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

    Not yet reported Mylan Pharmaceuticals Inc 24 participants Est. completion 2006-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT00651976

    Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

    Not yet reported Vanderbilt-Ingram Cancer Center 213 participants Est. completion 2018-09 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00688909

    Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

    Not yet reported Novartis Pharmaceuticals 261 participants Est. completion 2009-06 48 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00696072

    Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

    Not yet reported Bristol-Myers Squibb 120 participants Est. completion 2014-06 27 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00719966

    Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

    Mayo Clinic 109 participants Est. completion 2020-01-24 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00728949

    A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

    Not yet reported Eli Lilly and Company 93 participants Est. completion 2015-02 9 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00762294

    Anastrozole and Letrozole

    UConn Health 25 participants Est. completion 2011-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00770354

    Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer

    Not yet reported Antisoma Research 110 participants Est. completion 2011-08 2 sites Stand-alone
    Other conditions: Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT00790816

    Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

    Not yet reported Novartis Pharmaceuticals 500 participants Est. completion 2016-08-19 23 sites Stand-alone
    Other conditions: Neoplasms, Breast
    View official trial listing →
  • Terminated NCT NCT00796107

    A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

    Not yet reported Hoffmann-La Roche 6 participants Est. completion 2010-03-03 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT00804960

    Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?

    Not yet reported Center for Human Reproduction Est. completion 2010-04 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT00823004

    Antagonist/Letrozole in Poor Responders

    Not yet reported, Not yet reported Yazd Research & Clinical Center for Infertility 120 participants Est. completion 2009-10 1 site
    Other conditions: Ovarian Stimulation
    View official trial listing →
  • Completed NCT NCT00844350

    The Effect of Oxytocin (OT) and Oxytocin Plus Human Chorionic Gonadotropin (hCG), in Cycles Induced by Letrozole or Clomiphene Citrate

    Not yet reported Tabriz University 177 participants Est. completion 2007-10
    Other conditions: Ovarian Response
    View official trial listing →
  • Completed NCT NCT00863655

    Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

    Not yet reported Novartis Pharmaceuticals 724 participants Est. completion 2014-12-04 200 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00867217

    Vitamin D3 for Aromatase Inhibitor Induced Arthralgias

    Not yet reported Qamar Khan 160 participants Est. completion 2011-01 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00880009

    Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

    Not yet reported Pfizer 16 participants Est. completion 2010-05-31 11 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00893061

    Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

    Not yet reported Centre Oscar Lambret 44 participants Est. completion 2014-11-26 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00894608

    Letrozole Combined With Gonadotropins (Gn) for Ovarian Stimulation Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) in Patients With Polycystic Ovary Syndrome (PCOS)

    Not yet reported Yunyang Medical College 90 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Polycystic Ovarian Syndrome
    View official trial listing →
  • Completed NCT NCT00911313

    Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome

    Not yet reported Mansoura University 250 participants Est. completion 2009-01 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Status unknown NCT NCT00913016

    Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy

    Korean Breast Cancer Study Group 897 participants Est. completion 2012-06 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT00935558

    Dendritic Cell Based Therapy for Breast Cancer Patients

    Not yet reported Inge Marie Svane 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT00945360

    Aromatase Inhibitors for Treatment of Uterine Leiomyomas

    Not yet reported American University of Beirut Medical Center Est. completion 2011-05 1 site Stand-alone
    Other conditions: Symptomatic or Large Uterine Fibroids
    View official trial listing →
  • Completed NCT NCT00960960

    A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

    Not yet reported Genentech, Inc. 71 participants Est. completion 2015-12 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00963729

    Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

    Not yet reported Imperial College London 756 participants Est. completion 2011-03 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT00973505

    CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)

    Korea University Anam Hospital 100 participants Est. completion 2010-09 1 site
    Other conditions: Breast Neoplasms, Arthralgia, Arthritis, Genetic Polymorphism
    View official trial listing →
  • Completed NCT NCT00997373

    Letrozole as a Treatment of Endometrial Cancer

    Not yet reported University of California, Davis 43 participants Est. completion 2013-09 2 sites Stand-alone
    Other conditions: Endometrial Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT00999804

    Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

    Not yet reported Baylor Breast Care Center 128 participants Est. completion 2026-01 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01046578

    Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women

    Not yet reported University of Saskatchewan 41 participants Est. completion 2012-02 1 site Stand-alone
    Other conditions: Fertility
    View official trial listing →
  • Completed NCT NCT01058044

    Adherence to Oral Anticancer Treatment Using Electronic Monitoring System

    Not yet reported Centre Jean Perrin 33 participants 1 site
    Other conditions: Cancer
    View official trial listing →
  • Status unknown NCT NCT01058252

    Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF

    Galaxy Pharma (Pvt) Limited 30 participants Est. completion 2022-03 2 sites
    Other conditions: Primary Infertility, Secondary Infertility, Low Responders, Mild to Moderate Male Factor Infertility
    View official trial listing →
  • Active, not recruiting NCT NCT01068249

    Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

    Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2028-04-30 2 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Completed NCT NCT01068704

    Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

    Not yet reported Bristol-Myers Squibb 4 participants Est. completion 2010-12 8 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT01069211

    Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women

    Korean Breast Cancer Study Group 876 participants Est. completion 2017-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01077453

    Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

    Not yet reported National Cancer Institute (NCI) 112 participants 3 sites Stand-alone
    Other conditions: Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
    View official trial listing →
  • Completed NCT NCT01082068

    Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

    Not yet reported, Not yet reported Sanofi 72 participants Est. completion 2013-04 17 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01153672

    Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

    Not yet reported University of Washington 8 participants Est. completion 2016-08-11 1 site Stand-alone
    Other conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT01194440

    Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 63 participants Est. completion 2014-01 1 site Stand-alone
    Other conditions: Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01199367

    Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

    Not yet reported Kyowa Kirin Co., Ltd. 11 participants Est. completion 2012-12 5 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01205685

    Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 11 participants Est. completion 2011-07 3 sites Stand-alone
    Other conditions: Hormone-sensitive Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01208441

    RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

    Not yet reported National Cancer Institute (NCI) 28 participants 3 sites Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
    View official trial listing →
  • Completed NCT NCT01218581

    Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis

    Not yet reported, Not yet reported Mansoura University 32 participants Est. completion 2010-01 1 site
    Other conditions: the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis
    View official trial listing →
  • Completed NCT NCT01219153

    Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET

    Not yet reported Cairo University 136 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Terminated NCT NCT01220128

    Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

    Not yet reported GlaxoSmithKline 66 participants Est. completion 2014-11-14 36 sites Stand-alone
    Other conditions: Neoplasms, Breast
    View official trial listing →
  • Terminated NCT NCT01225172

    Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

    Not yet reported Bristol-Myers Squibb 77 participants Est. completion 2014-11-30 21 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01232075

    Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination

    Not yet reported Cairo University 214 participants Est. completion 2010-12 2 sites Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT01248494

    PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 72 participants Est. completion 2016-05 6 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01249456

    Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients

    Novartis Pharmaceuticals 392 participants Est. completion 2015-04 1 site
    Other conditions: Breast Cancer, Letrozole
    View official trial listing →
  • Completed NCT NCT01272570

    Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors

    University of Michigan 58 participants Est. completion 2013-08 1 site
    Other conditions: Breast Cancer, Xerostomia
    View official trial listing →
  • Completed NCT NCT01281137

    Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07

    ETOP IBCSG Partners Foundation 104 participants Est. completion 2019-05-15 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01296555

    A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

    Not yet reported Genentech, Inc. 674 participants Est. completion 2021-06-25 31 sites Stand-alone
    Other conditions: Solid Cancers, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01315912

    Dosage Optimization for Letrozole Treatment

    Not yet reported Bushehr University of Medical Science 44 participants Est. completion 2010-12 1 site
    Other conditions: Infertility
    View official trial listing →
  • Withdrawn NCT NCT01361945

    AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

    Not yet reported, Not yet reported Texas Tech University Health Sciences Center, El Paso Est. completion 2012-08 Stand-alone
    Other conditions: Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer, ER Positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT01367652

    Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

    Not yet reported Roxane Laboratories 28 participants Est. completion 2008-04 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01372982

    Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions

    Not yet reported Dr. Reddy's Laboratories Limited 36 participants Est. completion 2008-06 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01375452

    Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions

    Not yet reported Dr. Reddy's Laboratories Limited 36 participants Est. completion 2008-05 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01439711

    Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

    Not yet reported Alliance for Clinical Trials in Oncology 108 participants Est. completion 2018-01 32 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01446159

    Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

    Not yet reported MedImmune LLC 188 participants Est. completion 2019-06-28 71 sites Stand-alone
    Other conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01457703

    Reproductive Hormonal Alterations in Obesity

    Not yet reported University of Colorado, Denver 62 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT01475318

    Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy

    Not yet reported The University of Hong Kong 50 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Complete Abortion
    View official trial listing →
  • Completed NCT NCT01478477

    Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

    Not yet reported Ohio State University Comprehensive Cancer Center 44 participants Est. completion 2014-01-09 1 site
    Other conditions: Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
    View official trial listing →
  • Completed NCT NCT01491737

    A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

    Not yet reported Hoffmann-La Roche 258 participants Est. completion 2019-11-14 82 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01499160

    Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

    Not yet reported University of Maryland, Baltimore 7 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
    View official trial listing →
  • Terminated NCT NCT01551368

    Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients

    Not yet reported Mount Sinai Hospital, Canada 12 participants Est. completion 2017-07 1 site
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT01577017

    The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)

    Not yet reported Nik Hazlina 150 participants Est. completion 2012-03 Stand-alone
    Other conditions: Polycystic Ovarian Syndrome
    View official trial listing →
  • Completed NCT NCT01589367

    Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer

    Not yet reported Seoul National University Hospital 208 participants Est. completion 2018-08 1 site Stand-alone
    Other conditions: Hormone Receptor Positive Malignant Neoplasm of Breast
    View official trial listing →
  • Completed NCT NCT01619111

    DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

    Not yet reported Prof. Wolfgang Janni 105 participants Est. completion 2022-01 1 site Stand-alone
    Other conditions: HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells
    View official trial listing →
  • Completed NCT NCT01626222

    4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 301 participants Est. completion 2013-11 84 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01669343

    Aromatase Inhibitor Host Factors Study

    Not yet reported Samuel Lunenfeld Research Institute, Mount Sinai Hospital 121 participants Est. completion 2016-12 3 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT01684215

    A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

    Not yet reported Pfizer 61 participants Est. completion 2018-10-25 16 sites Stand-alone
    Other conditions: Neoplasms, Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT01686828

    T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

    Not yet reported, Not yet reported University of Washington 53 participants Est. completion 2017-12 1 site Stand-alone
    Type 2 diabetes Other conditions: Insulin Resistance, Obesity, Androgen Deficiency, Metabolic Disease
    View official trial listing →
  • Completed NCT NCT01698918

    Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

    Not yet reported Novartis Pharmaceuticals 202 participants Est. completion 2021-01-13 52 sites Stand-alone
    Other conditions: Hormone Receptor Positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT01709370

    Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

    Not yet reported Organisation for Oncology and Translational Research 45 participants 1 site Stand-alone
    Other conditions: ER Positive, HER2 Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT01720602

    Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

    Not yet reported University of Washington 15 participants Est. completion 2020-01 1 site Stand-alone
    Other conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT01791478

    BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 46 participants Est. completion 2022-10-06 2 sites Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT01793038

    Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women

    Not yet reported Mansoura Integrated Fertility Center 160 participants Est. completion 2014-09 1 site
    Other conditions: Polycystic Ovary Syndrome, Infertility
    View official trial listing →
  • Completed NCT NCT01797523

    A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

    Not yet reported M.D. Anderson Cancer Center 62 participants Est. completion 2026-02-04 6 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Completed NCT NCT01797718

    Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment

    Not yet reported, Not yet reported Helsinki University Central Hospital 35 participants Est. completion 2018-02-05 4 sites
    Other conditions: Constitutional Delay of Growth and Puberty
    View official trial listing →
  • Completed NCT NCT01870505

    BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 52 participants Est. completion 2022-02-28 1 site Stand-alone
    Other conditions: Metastatic or Locally-advanced Unresectable Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT01872260

    Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

    Not yet reported, Not yet reported Novartis Pharmaceuticals 255 participants Est. completion 2027-02-26 25 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01897441

    Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

    Not yet reported Albert Einstein College of Medicine 31 participants Est. completion 2023-10-25 1 site Stand-alone
    Other conditions: Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01919229

    A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

    Not yet reported Novartis Pharmaceuticals 14 participants Est. completion 2014-09 7 sites Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Completed NCT NCT01923168

    Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

    Not yet reported Novartis Pharmaceuticals 340 participants Est. completion 2017-07-08 86 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT01924078

    Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

    Not yet reported Fudan University 100 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT01926210

    Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders

    Not yet reported Huang Rui 500 participants Est. completion 2016-09 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Status unknown NCT NCT01948804

    The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.

    Not yet reported Pınar Özcan Cenksoy 100 participants Stand-alone
    Other conditions: Poor Responders Undergoing IVF
    View official trial listing →
  • Completed NCT NCT01958021

    Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

    Not yet reported Novartis Pharmaceuticals 668 participants Est. completion 2023-03-16 221 sites Stand-alone
    Other conditions: Advanced, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01973660

    PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 151 participants Est. completion 2017-12 22 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01989780

    Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

    Not yet reported Japan Breast Cancer Research Group 160 participants Est. completion 2019-06 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02000375

    A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 20 participants Est. completion 2016-02 8 sites Stand-alone
    Other conditions: Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer, Estrogen Receptor Negative Neoplasm, Progesterone Receptor Positive Tumor, Progesterone Receptor Negative Neoplasm, Androgen Receptor Gene Overexpression
    View official trial listing →
  • Completed NCT NCT02005887

    TRial on the Endocrine Activity of Neoadjuvant Degarelix

    Not yet reported ETOP IBCSG Partners Foundation 51 participants Est. completion 2017-08-25 7 sites Stand-alone
    Other conditions: Breast Cancer Invasive Nos
    View official trial listing →
  • Active, not recruiting NCT NCT02057133

    A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

    Not yet reported Eli Lilly and Company 198 participants Est. completion 2026-12 13 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT02095184

    GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

    Not yet reported University of Maryland, Baltimore 42 participants Est. completion 2024-08-02 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02101788

    Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 260 participants Est. completion 2025-10-27 501 sites
    Other conditions: Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT02109913

    Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

    Not yet reported Amsterdam UMC, location VUmc 175 participants Est. completion 2021-01 28 sites
    Other conditions: Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02115048

    Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

    Not yet reported Translational Research in Oncology 44 participants Est. completion 2018-11 26 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02128360

    Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve

    Not yet reported Sheba Medical Center 200 participants Est. completion 2016-06 1 site
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02137538

    Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

    Not yet reported Stanford University 79 participants Est. completion 2018-06-05 1 site
    Other conditions: Short Stature
    View official trial listing →
  • Terminated NCT NCT02213042

    Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 42 participants Est. completion 2020-06-04 51 sites
    Other conditions: Neoplasms, Breast
    View official trial listing →
  • Status unknown NCT NCT02214004

    Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

    Not yet reported Gangnam Severance Hospital 132 participants Est. completion 2019-06 14 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02221999

    Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

    Not yet reported, Not yet reported RenJi Hospital 250 participants Est. completion 2029-01 12 sites Stand-alone
    Other conditions: Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
    View official trial listing →
  • Completed NCT NCT02228681

    Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

    Not yet reported GOG Foundation 74 participants Est. completion 2024-08-22 26 sites Stand-alone
    Other conditions: Advanced, Persistent, or Recurrent Endometrial Cancer
    View official trial listing →
  • Terminated NCT NCT02236572

    Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

    Not yet reported Yale University 17 participants Est. completion 2021-03-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02246621

    A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

    Not yet reported Eli Lilly and Company 493 participants Est. completion 2026-12 155 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02273973

    A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

    Not yet reported Genentech, Inc. 334 participants Est. completion 2017-03-13 117 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02291913

    Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

    Not yet reported SCRI Development Innovations, LLC 48 participants Est. completion 2019-01-31 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02294773

    Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

    Not yet reported Midwest Fertility Specialists 13 participants Est. completion 2015-09 2 sites
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02297438

    A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

    Not yet reported Pfizer 340 participants Est. completion 2025-02-24 54 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02304107

    Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.

    Not yet reported Cairo University 140 participants Est. completion 2015-01 2 sites
    Other conditions: Infertility
    View official trial listing →
  • Status unknown NCT NCT02305693

    Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)

    Not yet reported Cairo University 140 participants 2 sites
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02333370

    A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    Not yet reported Novartis Pharmaceuticals 88 participants Est. completion 2022-09-29 15 sites Stand-alone
    Other conditions: Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02344472

    Detect V / CHEVENDO (Chemo vs. Endo)

    Not yet reported Prof. Wolfgang Janni 271 participants Est. completion 2025-01-31 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT02377479

    Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles

    Not yet reported University Hospitals Cleveland Medical Center 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02405156

    Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion

    Not yet reported, Not yet reported Ain Shams University 400 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Miscarriage
    View official trial listing →
  • Completed NCT NCT02411344

    Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy

    Not yet reported Istituto Oncologico Veneto IRCCS 64 participants Est. completion 2018-01-12 8 sites Stand-alone
    Other conditions: Endocrine Sensitive HER2+/HR+ Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02429999

    Letrozole in Assisted Reproductive Technology

    Not yet reported Assiut University 80 participants Est. completion 2017-12 1 site
    Other conditions: to Evaluate Letrozole as a Modality for Minimal Ovarian Stimulation in ICSI Cycles .
    View official trial listing →
  • Completed NCT NCT02448420

    Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 73 participants Est. completion 2023-11-30 35 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02450175

    Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls

    Not yet reported Sinai Hospital of Baltimore 50 participants Est. completion 2016-06 1 site
    Other conditions: Neoplasm
    View official trial listing →
  • Completed NCT NCT02470741

    Pilot of Letrozole for Uterine Myomas

    Not yet reported University of California, San Francisco 12 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Leiomyoma, Uterine Fibroids
    View official trial listing →
  • Status unknown NCT NCT02482740

    A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix

    Not yet reported Buddhist Tzu Chi General Hospital 44 participants Est. completion 2017-06 7 sites
    Other conditions: Uterine Cervical Neoplasms
    View official trial listing →
  • Completed NCT NCT02491983

    Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

    Not yet reported MedSIR 486 participants Est. completion 2020-01 48 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02499146

    Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

    Not yet reported Pfizer 26 participants Est. completion 2024-12-24 7 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT02511639

    Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

    Not yet reported Istituto Oncologico Veneto IRCCS 110 participants Est. completion 2020-07-31 16 sites Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT02538484

    Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

    Not yet reported The University of Texas Health Science Center at San Antonio 24 participants Est. completion 2020-03-26 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02585388

    Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

    Not yet reported ARCAGY/ GINECO GROUP 120 participants Est. completion 2017-05-15 47 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02592083

    Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

    Not yet reported Thomas Hatschek 10 participants Est. completion 2029-02 1 site
    Other conditions: Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT02603679

    Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

    Not yet reported Thomas Hatschek 181 participants Est. completion 2031-12-31 3 sites Stand-alone
    Other conditions: Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
    View official trial listing →
  • Completed NCT NCT02619162

    Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

    Not yet reported Centro Nacional de Investigaciones Oncologicas CARLOS III 25 participants Est. completion 2018-06 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT02619669

    Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

    Not yet reported Gary Schwartz Est. completion 2019-06-14 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02624973

    PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial

    Not yet reported Haukeland University Hospital 200 participants Est. completion 2030-06 7 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02630485

    Graceful Lifestyle Changes Study for PCOS and Infertility

    Not yet reported University of British Columbia 240 participants Est. completion 2018-08
    Other conditions: Polycystic Ovary Syndrome, Infertility
    View official trial listing →
  • Status unknown NCT NCT02647424

    A Comparison of Letrozole and Clomifene Citrate

    Not yet reported The University of Hong Kong 40 participants Est. completion 2017-12 1 site
    Other conditions: Polycystic Ovarian Syndrome, Subfertility
    View official trial listing →
  • Completed NCT NCT02648477

    Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

    Not yet reported City of Hope Medical Center 30 participants Est. completion 2023-12-30 6 sites Stand-alone
    Other conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT02657928

    Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

    Not yet reported Mayo Clinic 40 participants Est. completion 2020-10-07 3 sites Stand-alone
    Other conditions: Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma
    View official trial listing →
  • Completed NCT NCT02661932

    Fertility Preservation in Breast Cancer Patients

    Not yet reported Erasme University Hospital 65 participants Est. completion 2024-12 1 site Stand-alone
    Other conditions: Breast Neoplasms, Fertility
    View official trial listing →
  • Completed NCT NCT02670304

    Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS

    Not yet reported First Affiliated Hospital, Sun Yat-Sen University 100 participants Est. completion 2013-08 Stand-alone
    Other conditions: Ovarian Hyperstimulation Syndrome
    View official trial listing →
  • Completed NCT NCT02679755

    Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

    Not yet reported Pfizer 252 participants Est. completion 2019-07-25 34 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02684032

    A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

    Not yet reported Celcuity Inc 141 participants Est. completion 2022-01-19 41 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02686151

    The Letrozole Administration During Luteal Phase

    Not yet reported The Affiliated Hospital of Inner Mongolia Medical University 50 participants Est. completion 2024-12 1 site
    Other conditions: Ovarian Hyperstimulation Syndrome
    View official trial listing →
  • Completed NCT NCT02701348

    Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers

    Not yet reported NHS Tayside 31 participants Est. completion 2020-12-24 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02703649

    Administration of Single High Dose Letrozole for Ovulation Induction

    Not yet reported Mount Sinai Hospital, Canada 36 participants Est. completion 2020-07-31 2 sites Stand-alone
    Other conditions: Anovulation
    View official trial listing →
  • Completed NCT NCT02732808

    Dual Ovarian Stimulation in the Same IVF/ICSI Cycles for Treatment of Poor Ovarian Responders

    Not yet reported Royan Institute 50 participants Est. completion 2016-04 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02741154

    Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI

    Not yet reported Minia University 50 participants Est. completion 2017-09-03 1 site Stand-alone
    Other conditions: Infertility Indicated for ICSI
    View official trial listing →
  • Active, not recruiting NCT NCT02763566

    A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

    Not yet reported Eli Lilly and Company 463 participants Est. completion 2028-03 45 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02764541

    Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

    Not yet reported Dana-Farber Cancer Institute 195 participants Est. completion 2031-04 11 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02765373

    Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

    Chinese Academy of Medical Sciences 500 participants 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02767661

    Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

    Not yet reported Sun Yat-sen University 263 participants Est. completion 2023-08-25 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02778685

    Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

    Not yet reported City of Hope Medical Center 47 participants Est. completion 2026-03-30 7 sites Stand-alone
    Other conditions: Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT02802865

    Combined Letrozole and Clomid in Women With Infertility and PCOS

    Not yet reported Rachel Mejia 70 participants Est. completion 2019-02 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome, Infertility
    View official trial listing →
  • Completed NCT NCT02865681

    Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

    Not yet reported New Hope Fertility Center 4 participants Est. completion 2017-06-07 1 site Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02894398

    Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

    Not yet reported iOMEDICO AG 388 participants Est. completion 2023-02-15 70 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Completed NCT NCT02900105

    Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia.

    Not yet reported KK Women's and Children's Hospital 28 participants Est. completion 2017-03 1 site Stand-alone
    Other conditions: Azoospermia, Nonobstructive, Oligozoospermia
    View official trial listing →
  • Active, not recruiting NCT NCT02918084

    CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

    Not yet reported IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 1000 participants Est. completion 2028-06 74 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02946684

    Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

    Not yet reported, Not yet reported Sven O. Skouby 129 participants Est. completion 2018-10-30 4 sites
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT02980965

    Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

    Not yet reported Fudan University 249 participants Est. completion 2017-02 1 site Stand-alone
    Other conditions: Breast Cancer Female
    View official trial listing →
  • Completed NCT NCT02995772

    Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

    Not yet reported Dharmais National Cancer Center Hospital 122 participants Est. completion 2018-11 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03009838

    Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome

    Not yet reported Assiut University 150 participants Est. completion 2023-08 1 site
    Other conditions: Infertility
    View official trial listing →
  • Status unknown NCT NCT03024580

    A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

    Not yet reported Instituto Nacional de Cancer, Brazil 20 participants Est. completion 2020-09 1 site
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Terminated NCT NCT03050398

    A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

    Not yet reported Novartis Pharmaceuticals 8 participants Est. completion 2019-03-08 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03056755

    Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

    Not yet reported Novartis Pharmaceuticals 383 participants Est. completion 2024-11-12 94 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT03058939

    Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

    Not yet reported University of Chicago Est. completion 2019-06 1 site
    Other conditions: Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
    View official trial listing →
  • Completed NCT NCT03078751

    Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

    Not yet reported Novartis Pharmaceuticals 54 participants Est. completion 2020-03-09 33 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03096847

    Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 502 participants Est. completion 2020-02-06 84 sites Stand-alone
    Other conditions: Advanced Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03111615

    HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer

    Not yet reported Centro Hospitalar Lisboa Ocidental 90 participants Est. completion 2020-05-01 1 site
    Other conditions: Hormone Dependent Neoplasms, Breast Cancer Female
    View official trial listing →
  • Terminated NCT NCT03128619

    Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

    Not yet reported Jonsson Comprehensive Cancer Center 10 participants Est. completion 2022-03-31 1 site Stand-alone
    Other conditions: Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03161353

    Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

    Not yet reported MedSIR 377 participants Est. completion 2026-11-01 56 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03179904

    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

    Not yet reported Mayo Clinic 17 participants Est. completion 2026-03-13 3 sites Stand-alone
    Other conditions: Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT03181919

    Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS

    Not yet reported Benha University 90 participants Est. completion 2017-03-01 Stand-alone
    Other conditions: Infertility Poly Cystic Ovary
    View official trial listing →
  • Completed NCT NCT03184090

    Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

    Not yet reported MedSIR 33 participants Est. completion 2020-10-27 15 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03241472

    Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole

    Not yet reported Assiut University 100 participants Est. completion 2017-06 Stand-alone
    Other conditions: Infertility
    View official trial listing →
  • Completed NCT NCT03248427

    Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.

    Not yet reported SOLTI Breast Cancer Research Group 106 participants Est. completion 2019-07-20 21 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03272477

    Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

    Not yet reported Palleos Healthcare GmbH 257 participants Est. completion 2024-03-04 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT03306472

    A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 198 participants Est. completion 2023-10-31 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03321981

    MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

    Not yet reported Merus B.V. 105 participants Est. completion 2023-07-26 25 sites
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT03355157

    A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

    Not yet reported GBG Forschungs GmbH 130 participants Est. completion 2024-08-30 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03378297

    IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC

    Not yet reported Haukeland University Hospital 26 participants Est. completion 2023-01-05 2 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT03397537

    Neoadjuvant Endocrine Therapy in Breast Cancer

    Not yet reported Guangdong Provincial People's Hospital 46 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Highly Endocrine Responsive Operable Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03400683

    Different Methods of Termination of Second Trimester Abortion

    Not yet reported Cairo University 150 participants Est. completion 2018-07 1 site
    Other conditions: Induction of Abortion
    View official trial listing →
  • Active, not recruiting NCT NCT03425838

    Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

    Not yet reported Borstkanker Onderzoek Groep 1050 participants Est. completion 2028-12 72 sites
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Terminated NCT NCT03439046

    Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

    Not yet reported Novartis Pharmaceuticals 287 participants Est. completion 2023-12-11 41 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03455426

    Intrauterine Insemination With Letrozole Versus in Natural Cycle

    Not yet reported Peking University Third Hospital 100 participants Est. completion 2019-12-31 1 site Stand-alone
    Other conditions: Infertility, Intrauterine Insemination
    View official trial listing →
  • Completed NCT NCT03481998

    A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

    Not yet reported, Not yet reported Jiangsu HengRui Medicine Co., Ltd. 104 participants Est. completion 2022-07-30 4 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03497702

    Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

    Not yet reported National Cancer Center, Korea 114 participants Est. completion 2024-01 1 site Stand-alone
    Other conditions: Breast Cancer, Invasive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03507465

    Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

    Not yet reported, Not yet reported Guangdong Provincial People's Hospital 290 participants Est. completion 2020-11-29 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03540979

    Endometrial Preparation in Frozen Embryo Transfer Cycles

    Not yet reported Meir Medical Center 100 participants Est. completion 2019-12 Stand-alone
    Other conditions: Reproductive Behavior
    View official trial listing →
  • Completed NCT NCT03541863

    Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

    Fudan University 131 participants Est. completion 2018-12-20 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03554044

    T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

    Not yet reported University of California, San Francisco 20 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT03625531

    A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS

    Not yet reported Hongxia Ma 1103 participants Est. completion 2025-01-22 1 site
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT03628066

    Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

    Not yet reported NSABP Foundation Inc 24 participants Est. completion 2021-01-30 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03628625

    Letrozole Pretreatment With Misoprostol fInduction of Abortion In First-Trimester Missed Miscarriage

    Not yet reported Ain Shams Maternity Hospital 80 participants Est. completion 2018-12-10 1 site Stand-alone
    Other conditions: Miscarriage, Missed Abortion
    View official trial listing →
  • Completed NCT NCT03633331

    Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 93 participants Est. completion 2026-02-27 447 sites Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT03644186

    To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

    Not yet reported ETOP IBCSG Partners Foundation 147 participants Est. completion 2023-04-14 54 sites Stand-alone
    Other conditions: Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03664050

    Laparoscopic Ovarian Drilling Versus Letrozole In Clomiphene Citrate Resistant Polycystic Ovary

    Not yet reported Ain Shams University 90 participants Est. completion 2018-12-01 1 site Stand-alone
    Other conditions: Induction of Ovulation
    View official trial listing →
  • Active, not recruiting NCT NCT03701334

    A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

    Not yet reported Novartis Pharmaceuticals 5101 participants Est. completion 2030-05-29 386 sites Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03709082

    Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

    Not yet reported, Not yet reported University of Kansas Medical Center 3 participants Est. completion 2021-02-03 5 sites Stand-alone
    Other conditions: HER2-positive Breast Cancer, Breast Cancer Metastatic
    View official trial listing →
  • Status unknown NCT NCT03772353

    Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

    Not yet reported, Not yet reported Fudan University 59 participants Est. completion 2025-12-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03778931

    Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

    Not yet reported Stemline Therapeutics, Inc. 478 participants Est. completion 2024-08-22 244 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03819010

    Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -

    Not yet reported MedSIR 66 participants Est. completion 2019-12-31 18 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03820830

    Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

    Not yet reported ETOP IBCSG Partners Foundation 405 participants Est. completion 2029-01-01 53 sites Stand-alone
    Other conditions: Breast Cancer Recurrent
    View official trial listing →
  • Completed NCT NCT03822468

    Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

    Not yet reported Novartis Pharmaceuticals 376 participants Est. completion 2024-08-30 89 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03839823

    Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 222 participants Est. completion 2023-05-10 50 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03870919

    Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

    Not yet reported UNICANCER 200 participants Est. completion 2027-10-23 26 sites
    Other conditions: Breast Cancer Stage IV, Radiotherapy, Surgery
    View official trial listing →
  • Active, not recruiting NCT NCT03900637

    PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

    Not yet reported Seoul National University Hospital 122 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03900884

    Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

    Not yet reported Peter MacCallum Cancer Centre, Australia 17 participants Est. completion 2025-12 3 sites Stand-alone
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Status unknown NCT NCT03901170

    Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?

    Not yet reported National Taiwan University Hospital 300 participants Est. completion 2021-04-08 1 site Stand-alone
    Other conditions: Investigative Techniques, Reproductive Techniques, Reproductive Techniques, Assisted
    View official trial listing →
  • Status unknown NCT NCT03906669

    A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

    Not yet reported St Vincent's Hospital 200 participants Est. completion 2024-04 1 site Stand-alone
    Other conditions: Early-stage Breast Cancer, Hormone Receptor Positive Tumor
    View official trial listing →
  • Status unknown NCT NCT03910712

    Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

    Not yet reported Peking Union Medical College Hospital 250 participants Est. completion 2023-12-01 Stand-alone
    Other conditions: Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
    View official trial listing →
  • Status unknown NCT NCT03925233

    Breast Cancer Treatment Based on Organ-like Culture

    Xijing Hospital 300 participants Est. completion 2021-12-15 1 site
    Other conditions: Breast Cancer Organoids
    View official trial listing →
  • Completed NCT NCT03936270

    Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

    Not yet reported Latin American Cooperative Oncology Group 43 participants Est. completion 2023-05-02 5 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT03948568

    Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

    Not yet reported Ottawa Hospital Research Institute 262 participants Est. completion 2022-04-09 1 site
    Other conditions: Early-stage Breast Cancer
    View official trial listing →
  • Completed NCT NCT03956654

    A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer

    Universitaire Ziekenhuizen KU Leuven 78 participants Est. completion 2024-06-30 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03959891

    AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

    Not yet reported Massachusetts General Hospital 77 participants Est. completion 2027-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03966898

    A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 426 participants Est. completion 2023-12-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT03969121

    Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

    Not yet reported Kyoto Breast Cancer Research Network 141 participants Est. completion 2021-12-23 25 sites
    Other conditions: Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
    View official trial listing →
  • Withdrawn NCT NCT03988114

    A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

    Not yet reported Eli Lilly and Company Est. completion 2023-03-23 119 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT04002141

    Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

    Not yet reported University of California, San Francisco 60 participants Est. completion 2025-01-01 1 site Stand-alone
    Other conditions: Endometriosis, Ovarian Hyperstimulation
    View official trial listing →
  • Withdrawn NCT NCT04002635

    Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)

    Not yet reported CRG UZ Brussel Est. completion 2022-04-01 Stand-alone
    Other conditions: Infertility, Female, Polycystic Ovary Syndrome, IVF, Ovulation Disorder
    View official trial listing →
  • Withdrawn NCT NCT04088032

    Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

    Not yet reported Alison Stopeck Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
    View official trial listing →
  • Active, not recruiting NCT NCT04095364

    Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not yet reported NRG Oncology 450 participants Est. completion 2028-02-01 909 sites Stand-alone
    Other conditions: Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04095390

    A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

    Not yet reported Jinming Yu 60 participants Est. completion 2022-08-30 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04102618

    A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

    Not yet reported Oncolytics Biotech 26 participants Est. completion 2022-04-20 14 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04129216

    The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

    Not yet reported Johns Hopkins University 30 participants Est. completion 2022-11-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04130152

    Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

    Not yet reported SOLTI Breast Cancer Research Group 22 participants Est. completion 2022-02-24 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04158362

    Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

    Not yet reported UNICANCER 180 participants Est. completion 2032-06 2 sites Stand-alone
    Other conditions: Cancer Metastatic
    View official trial listing →
  • Status unknown NCT NCT04169451

    IUI With Letrozole Versus in Natural Cycle

    Not yet reported Peking University Third Hospital 982 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Intrauterine Insemination, Unexplained Infertility
    View official trial listing →
  • Completed NCT NCT04176354

    Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

    Pfizer 813 participants Est. completion 2019-09-27 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT04177693

    Pharmacokinetics and Hepatic Safety of EGCG

    Not yet reported Yale University 39 participants Est. completion 2022-01-31 1 site Stand-alone
    Other conditions: Uterine Fibroids
    View official trial listing →
  • Active, not recruiting NCT NCT04188548

    A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

    Not yet reported Eli Lilly and Company 379 participants Est. completion 2027-12 74 sites Stand-alone
    Other conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
    View official trial listing →
  • Terminated NCT NCT04191382

    Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

    Not yet reported Sanofi 105 participants Est. completion 2021-05-28 32 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04193930

    Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles

    Not yet reported Assiut University Est. completion 2021-01-01 1 site
    Other conditions: ART
    View official trial listing →
  • Withdrawn NCT NCT04220476

    CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

    Not yet reported Weill Medical College of Cornell University Est. completion 2028-12-31
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04256941

    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2023-09-22 1 site
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04258163

    Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 760 participants Est. completion 2019-07-01 3 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04272801

    Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

    Not yet reported Shayna Showalter, MD 84 participants Est. completion 2026-06-01 2 sites Stand-alone
    Other conditions: Breast Cancer Female
    View official trial listing →
  • Status unknown NCT NCT04282031

    A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

    Not yet reported, Not yet reported Beta Pharma (Suzhou) Co., Ltd. 224 participants Est. completion 2025-06-30 1 site Stand-alone
    Other conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04289805

    Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)

    Not yet reported Erasme University Hospital 96 participants Est. completion 2025-01-15 6 sites Stand-alone
    Other conditions: Breast Neoplasm Malignant Female
    View official trial listing →
  • Active, not recruiting NCT NCT04293393

    Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

    Not yet reported Spanish Breast Cancer Research Group 200 participants Est. completion 2033-02-28 28 sites Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Completed NCT NCT04294225

    Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

    Not yet reported Mayo Clinic 161 participants Est. completion 2022-12-12 3 sites Stand-alone
    Other conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04300790

    Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

    Not yet reported MedSIR 69 participants Est. completion 2025-03-16 19 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04310293

    Novel Therapy for Poor Responders Management

    Not yet reported Al Baraka Fertility Hospital 100 participants Est. completion 2020-08-01 1 site
    Other conditions: Poor Ovarian Response
    View official trial listing →
  • Status unknown NCT NCT04325295

    LOD vs Gn in Anovulatory PCOs Resistant to First Line Agents

    Not yet reported Assiut University 200 participants Est. completion 2022-08
    Other conditions: Polycystic Ovary Syndrome, Anovulation
    View official trial listing →
  • Status unknown NCT NCT04341545

    Letrozole in Tubal Ectopic Pregnancy

    Not yet reported Queen Mary Hospital, Hong Kong 214 participants Est. completion 2025-03-31 1 site Stand-alone
    Other conditions: Tubal Pregnancy
    View official trial listing →
  • Completed NCT NCT04352777

    Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

    Not yet reported Duke University 18 participants Est. completion 2025-06-25 1 site
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT04383275

    Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

    Not yet reported Fudan University 367 participants Est. completion 2031-07-06 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04393285

    Abemaciclib and Letrozole to Treat Endometrial Cancer

    Not yet reported Gynecologic Oncology Group 53 participants Est. completion 2026-12-31 29 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Completed NCT NCT04460898

    RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

    Pfizer 195 participants Est. completion 2019-06-24 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04478266

    Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

    Not yet reported Sanofi 1068 participants Est. completion 2023-05-26 249 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04488107

    Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

    Not yet reported, Not yet reported Ahon Pharmaceutical Co., Ltd. 78 participants Est. completion 2022-06-30 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT04524728

    Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

    Istituti Clinici Scientifici Maugeri SpA 191 participants Est. completion 2020-06 1 site
    Other conditions: Breast, Neoplasm Malignant, Female
    View official trial listing →
  • Active, not recruiting NCT NCT04539496

    A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

    Not yet reported, Not yet reported Sihuan Pharmaceutical Holdings Group Ltd. 402 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Metastasis Solid Tumors, Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04553133

    PF-07104091 as a Single Agent and in Combination Therapy

    Not yet reported Pfizer 157 participants Est. completion 2026-12-31 22 sites Stand-alone
    Other conditions: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04571437

    Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

    Not yet reported Cairo University 204 participants Est. completion 2022-04-30 1 site
    Other conditions: Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04577001

    Letrozole in Patients With Hepatopulmonary Syndrome

    Not yet reported Mayo Clinic 1 participants Est. completion 2021-03-26 1 site Stand-alone
    Other conditions: Hepatopulmonary Syndrome
    View official trial listing →
  • Status unknown NCT NCT04590482

    Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion

    Not yet reported Shereen Rady Abou El-fetouh 110 participants Est. completion 2021-05-08 Stand-alone
    Other conditions: Missed Abortion
    View official trial listing →
  • Status unknown NCT NCT04593108

    Misoprostol With or Without Letrozole in Treatment of Missed Miscarriage

    Dr.Dalia Mohammed Al Sayed Zaki 320 participants Est. completion 2020-11-15 1 site
    Other conditions: Missed Abortion
    View official trial listing →
  • Completed NCT NCT04603183

    ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

    Not yet reported MedSIR 162 participants Est. completion 2025-06-30 31 sites Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT04619914

    the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women

    Not yet reported Laylay Mohammed Khalleefah Alhibshi 160 participants Est. completion 2019-08-10 1 site Stand-alone
    Other conditions: Endometrial Thickness, Pregnancy Rate
    View official trial listing →
  • Terminated NCT NCT04657679

    Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

    Not yet reported Georgetown University 21 participants Est. completion 2023-10-30 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04714619

    CB-103 Plus NSAI In Luminal Advanced Breast Cancer

    Not yet reported MedSIR 2 participants Est. completion 2022-04-26 2 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04720807

    Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

    Not yet reported Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 30 participants Est. completion 2023-09-30 1 site Stand-alone
    Other conditions: Platinum-resistant Recurrent Ovarian Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04733118

    Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

    Not yet reported MedSIR 393 participants Est. completion 2028-03 41 sites Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Completed NCT NCT04735367

    Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

    Pfizer 42 participants Est. completion 2023-09-29 13 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04834791

    Letrozole Versus Gonadotropins in Clomiphene Citrate Resistance

    Not yet reported Tanta University 70 participants Est. completion 2019-10-31 1 site Stand-alone
    Other conditions: Clomiphene Citrate Resistance, Ovulation Induction, Letrozole, Gonadotropins
    View official trial listing →
  • Active, not recruiting NCT NCT04895761

    Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

    Not yet reported Providence Health & Services 6 participants Est. completion 2026-09-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04906395

    Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

    Not yet reported Tolmar Inc. 250 participants Est. completion 2026-04-30 59 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04931342

    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not yet reported Hoffmann-La Roche 176 participants Est. completion 2028-05-30 41 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Status unknown NCT NCT04942899

    Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

    Not yet reported Assiut University 70 participants Est. completion 2025-05-31
    Other conditions: Metastasis Breast
    View official trial listing →
  • Status unknown NCT NCT04987632

    Effect of Acupuncture Plus Governor Vessel Moxibustion Combined With Letrozole on Live Birth in Anovulatory Infertile Women With Spleen-kidney Yang Deficiency PCOS

    Not yet reported Qiu-ping Lin 90 participants Est. completion 2022-12-31 Stand-alone
    Other conditions: PCOS, Infertility, Female
    View official trial listing →
  • Active, not recruiting NCT NCT05041842

    Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

    Not yet reported UNICANCER 53 participants Est. completion 2026-04-30 16 sites Stand-alone
    Other conditions: Metastatic Breast Cancer With a Isolated Brain Progression
    View official trial listing →
  • Terminated NCT NCT05085002

    A Study of Lerociclib in Participants With Advanced Breast Cancer

    Not yet reported EQRx, Inc. 100 participants Est. completion 2023-11-29 21 sites
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT05131893

    Neoadjuvant Treatment of Breast Cancer

    National Institute of Oncology, Hungary 300 participants Est. completion 2031-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05150652

    Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

    Not yet reported Irada Ibrahim-zada 8 participants Est. completion 2026-06-10 1 site Stand-alone
    Other conditions: Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT05157672

    Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon

    Not yet reported Washington State University 16 participants Est. completion 2024-08-31 1 site Stand-alone
    Other conditions: Interaction Drug Food
    View official trial listing →
  • Active, not recruiting NCT NCT05161195

    Roll-over Study to Allow Continued Access to Ribociclib

    Not yet reported Novartis Pharmaceuticals 134 participants Est. completion 2030-08-14 73 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05163106

    Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

    Not yet reported University Hospital, Akershus 85 participants Est. completion 2024-07-30 1 site Stand-alone
    Other conditions: Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Locally Advanced Breast Cancer, Luminal A Breast Cancer, Luminal B Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05164952

    Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

    Not yet reported Assiut University 50 participants Est. completion 2023-09-30 1 site
    Other conditions: Use of Zoledronic Acid in Breast Cancer
    View official trial listing →
  • Completed NCT NCT05166668

    Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle

    Not yet reported Menoufia University 200 participants Est. completion 2025-02-10 1 site
    Other conditions: Ovarian Stimulation
    View official trial listing →
  • Withdrawn NCT NCT05168865

    Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.

    Not yet reported Dubai Fertility Center Est. completion 2024-04-01 Stand-alone
    Other conditions: Frozen Embryo Transfer, Polycystic Ovarian Disease, Letrozole, Hormone Replacement Therapy, Live Birth, Miscarriage
    View official trial listing →
  • Completed NCT NCT05198050

    Letrozole in Induction of Abortion of Anembryonic Pregnancy

    Not yet reported Cairo University 96 participants Est. completion 2022-09-30 1 site
    Other conditions: Anembryonic Pregnancy
    View official trial listing →
  • Terminated NCT NCT05205837

    A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

    Not yet reported Rigshospitalet, Denmark 8 participants Est. completion 2023-08-15 1 site
    Other conditions: Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
    View official trial listing →
  • Completed NCT NCT05207644

    Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation

    Not yet reported Gynuity Health Projects 40 participants Est. completion 2022-04-30 1 site
    Other conditions: Pregnancy
    View official trial listing →
  • Terminated NCT NCT05207709

    Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

    Not yet reported SOLTI Breast Cancer Research Group 61 participants Est. completion 2026-03-26 71 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05226871

    Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

    Not yet reported Pfizer 35 participants Est. completion 2029-12-31 23 sites
    Other conditions: Breast Cancer, Head and Neck Cancer
    View official trial listing →
  • Status unknown NCT NCT05227391

    Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Transfer in Women With PCOS

    Not yet reported Reproductive & Genetic Hospital of CITIC-Xiangya 1078 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: PCOS
    View official trial listing →
  • Withdrawn NCT NCT05238831

    SMMART Adaptive Clinical Treatment (ACT) Trial

    Not yet reported OHSU Knight Cancer Institute Est. completion 2026-05-31 Stand-alone
    Other conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05257395

    A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

    Not yet reported Xuanzhu Biopharmaceutical Co., Ltd. 397 participants Est. completion 2030-09-05 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05296746

    Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 1100 participants Est. completion 2031-12-01 51 sites Stand-alone
    Other conditions: Breast Cancer Stage II
    View official trial listing →
  • Completed NCT NCT05304273

    Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages

    Not yet reported Calcutta National Medical College and Hospital 120 participants Est. completion 2024-10-01 1 site Stand-alone
    Other conditions: Miscarriage
    View official trial listing →
  • Status unknown NCT NCT05337657

    A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

    Not yet reported Genor Biopharma Co., Ltd. 10 participants Est. completion 2024-02-01 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05362799

    Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles

    Not yet reported Menoufia University 176 participants Est. completion 2023-12-31
    Other conditions: Infertility, Female
    View official trial listing →
  • Status unknown NCT NCT05411380

    Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

    Not yet reported wang shusen 73 participants Est. completion 2025-04-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05439499

    This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

    Not yet reported Ahon Pharmaceutical Co., Ltd. 434 participants Est. completion 2025-03-02 1 site Stand-alone
    Other conditions: Advanced Breast Cancer, Female Breast Cancer
    View official trial listing →
  • Terminated NCT NCT05454358

    Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

    Not yet reported, Not yet reported Fudan University 12 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Status unknown NCT NCT05457335

    2.Comparison of the Live Birth Rate of PGT Versus Expectant Management in Patients With RPL

    Shanghai First Maternity and Infant Hospital 280 participants Est. completion 2024-07-15 1 site
    Other conditions: Pregnancy Outcome, Time-to-Pregnancy
    View official trial listing →
  • Active, not recruiting NCT NCT05463601

    Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 132 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05469750

    Dalpiciclib Plus Letrozole and Capecitabine

    Not yet reported Fujian Medical University Union Hospital 48 participants Est. completion 2024-08 Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05512416

    Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

    Not yet reported The Affiliated Hospital of Qingdao University 35 participants Est. completion 2024-05 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05512780

    Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

    Not yet reported Hebei Medical University Fourth Hospital 30 participants Est. completion 2024-08-10 Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Status unknown NCT NCT05523609

    Vitamin D and Calcium Supplementation in Breast Cancer

    Not yet reported, Not yet reported Tanta University 40 participants Est. completion 2024-10 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Enrolling by invitation NCT NCT05645536

    Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

    Not yet reported Tolmar Inc. 250 participants Est. completion 2030-03 47 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05677828

    SMART Protocol vs Antagonist Protocol in IVF

    Clinique Ovo 426 participants Est. completion 2023-01-31 1 site
    Other conditions: Diminished Ovarian Reserve
    View official trial listing →
  • Completed NCT NCT05702957

    Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome

    Not yet reported, Not yet reported Services Institute of Medical Sciences, Pakistan 220 participants Est. completion 2019-12 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome, Infertility
    View official trial listing →
  • Status unknown NCT NCT05705505

    Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

    Not yet reported, Not yet reported Traws Pharma, Inc. 60 participants Est. completion 2026-02 8 sites Stand-alone
    Other conditions: Endometrioid Endometrial Cancer
    View official trial listing →
  • Withdrawn NCT NCT05712941

    Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

    Not yet reported EQRx International, Inc. Est. completion 2025-03 Stand-alone
    Other conditions: Endometrial Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05780567

    Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1946 participants Est. completion 2027-01 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05789771

    Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

    Blokhin's Russian Cancer Research Center 136 participants Est. completion 2022-12-01 1 site
    Other conditions: HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease
    View official trial listing →
  • Status unknown NCT NCT05792410

    A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

    Not yet reported, Not yet reported Jiangsu HengRui Medicine Co., Ltd. 300 participants Est. completion 2025-02-27
    Other conditions: HER2 Low Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05800197

    Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

    Blokhin's Russian Cancer Research Center 300 participants Est. completion 2025-01-15 1 site
    Other conditions: Breast Cancer, Neoadjuvant Endocrine Therapy
    View official trial listing →
  • Status unknown NCT NCT05800756

    Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

    Not yet reported Yantai Yuhuangding Hospital 30 participants Est. completion 2025-07-30 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05839561

    Monotherapy With Letrozole in Tubal Pregnancy

    Not yet reported Jagiellonian University 22 participants Est. completion 2023-06-30 1 site
    Other conditions: Tubal Pregnancy Unruptured
    View official trial listing →
  • Status unknown NCT NCT05861830

    Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

    Not yet reported Peking Union Medical College Hospital 80 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT05874518

    Clinical Observation of Warm Needling Combined With and Electroacupuncture Therapy on Ovulatory Dysfunction

    Not yet reported Liuzhou Maternity and Child Healthcare Hospital 70 participants Est. completion 2022-04-30 1 site
    Other conditions: Warm Needling, Electroacupuncture, Ovulation Dysfunction
    View official trial listing →
  • Active, not recruiting NCT NCT05909397

    Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

    Not yet reported Pfizer 59 participants Est. completion 2026-12-30 29 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05952557

    An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

    Not yet reported AstraZeneca 5511 participants Est. completion 2037-05-06 661 sites
    Other conditions: Breast Cancer, Early Breast Cancer
    View official trial listing →
  • Completed NCT NCT05969184

    Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

    Not yet reported Peking University Cancer Hospital & Institute 94 participants Est. completion 2026-06-25 2 sites Stand-alone
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Active, not recruiting NCT NCT06001762

    TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

    Not yet reported Dana-Farber Cancer Institute 90 participants Est. completion 2027-01-01 12 sites Stand-alone
    Other conditions: Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06016738

    OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

    Not yet reported Olema Pharmaceuticals, Inc. 510 participants Est. completion 2028-02-29 233 sites
    Other conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT06047184

    Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

    Not yet reported BeBetter Med Inc 100 participants Est. completion 2024-01-30 2 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT06086340

    Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

    Pfizer 779 participants Est. completion 2024-01-24 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06120595

    Intervention Study Based on Real-world Data to Improve Quality of Life After Breast Cancer Treatment, the REBECCA-2 Study

    Not yet reported Helse Stavanger HF 81 participants Est. completion 2025-05-01 1 site
    Other conditions: Cancer Related Fatigue
    View official trial listing →
  • Not yet recruiting NCT NCT06223698

    Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer

    Not yet reported Region Örebro County 3832 participants Est. completion 2035-05-02 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06311383

    A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

    Novartis Pharmaceuticals 2610 participants Est. completion 2025-03-10 265 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06315205

    Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

    Not yet reported Rovi Pharmaceuticals Laboratories 84 participants Est. completion 2026-03-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT06341283

    A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

    The Affiliated Hospital of Qingdao University 200 participants Est. completion 2025-07-01 1 site
    Other conditions: Breast Cancer, Neoplasms, Breast Diseases
    View official trial listing →
  • Status unknown NCT NCT06346457

    Breast Cancer & Antiestrogenic Therapy & Brain

    International Research Training Group 2804 180 participants Est. completion 2026-04-01 1 site
    Other conditions: Breast Cancer Female, Healthy Female, Menopause, Anti-estrogenic Therapy
    View official trial listing →
  • Completed NCT NCT06367712

    Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol

    Not yet reported Egymedicalpedia 132 participants Est. completion 2023-11-10 1 site
    Other conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
    View official trial listing →
  • Completed NCT NCT06375707

    First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 74 participants Est. completion 2026-05-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06405243

    Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

    Not yet reported Beni-Suef University 100 participants Est. completion 2024-12-31 2 sites Stand-alone
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT06426979

    Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy

    Not yet reported Zagazig University 200 participants Est. completion 2024-01-01 1 site
    Other conditions: Pregnancy Tubal
    View official trial listing →
  • Completed NCT NCT06452511

    Comparing the Effect of Metformin vs. Pep2dia as an Adjunct to Letrozole on Ovulation Induction and Pregnancy Outcomes in Overweight Women With PCOS

    Not yet reported Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy 100 participants Est. completion 2025-03-25 1 site
    Other conditions: PCOS
    View official trial listing →
  • Completed NCT NCT06452719

    Letrozole and Misoprostol for Early Pregnancy Loss Management

    Not yet reported University of Pennsylvania 19 participants Est. completion 2026-05-14 1 site Stand-alone
    Other conditions: Early Pregnancy Loss, Miscarriage in First Trimester, Miscarriage
    View official trial listing →
  • Completed NCT NCT06465368

    A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

    Not yet reported Pfizer 121 participants Est. completion 2025-07-10 51 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06486870

    Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women

    Not yet reported Cairo University 183 participants Est. completion 2024-01-31 1 site Stand-alone
    Other conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
    View official trial listing →
  • Completed NCT NCT06570031

    ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

    Not yet reported Ono Pharmaceutical Co., Ltd. 46 participants Est. completion 2026-04-30 13 sites Stand-alone
    Other conditions: Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06590857

    Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

    Not yet reported, Not yet reported RayzeBio, Inc. 16 participants Est. completion 2033-11 31 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06605690

    An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

    Not yet reported Liu Shu 30 participants Est. completion 2026-08-31 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06607601

    CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

    Aetion, Inc. 724 participants Est. completion 2023-07-20
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06613373

    An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

    Not yet reported Jiangsu Famous Medical Technology Co., Ltd. 30 participants Est. completion 2026-10-30 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Enrolling by invitation NCT NCT06650748

    Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

    Not yet reported Peking University 100 participants Est. completion 2028-04-01 1 site Stand-alone
    Other conditions: Breast Cancer, Early-stage Breast Cancer
    View official trial listing →
  • Suspended NCT NCT06671912

    Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

    Not yet reported Alliance for Clinical Trials in Oncology 1556 participants Est. completion 2031-11-30 732 sites
    Other conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
    View official trial listing →
  • Active, not recruiting NCT NCT06706414

    NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia

    Not yet reported, Not yet reported Martin Blomberg Jensen 16 participants Est. completion 2026-08 1 site Stand-alone
    Other conditions: Infertility, Male
    View official trial listing →
  • Not yet recruiting NCT NCT06733727

    Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage

    Not yet reported The University of Hong Kong 884 participants Est. completion 2028-06-05
    Other conditions: Silent Miscarriage
    View official trial listing →
  • Active, not recruiting NCT NCT06760637

    Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

    Not yet reported Pfizer 1035 participants Est. completion 2037-12-29 463 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06810492

    The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

    Not yet reported Hongmei Zheng, PhD 40 participants Est. completion 2027-12-01
    Other conditions: Breast Cancer Stage III, Breast Cancer Stage II
    View official trial listing →
  • Not yet recruiting NCT NCT06913075

    FET in Adenomyosis

    Not yet reported Indira IVF Hospital Pvt Ltd 700 participants Est. completion 2026-12-23 1 site
    Other conditions: Adenomyosis
    View official trial listing →
  • Not yet recruiting NCT NCT07005557

    Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

    Not yet reported Fudan University 1244 participants Est. completion 2035-05-15 Stand-alone
    Other conditions: Breast Cancer, Adjuvant Therapy
    View official trial listing →
  • Not yet recruiting NCT NCT07061717

    Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 474 participants Est. completion 2029-07-01 1 site Stand-alone
    Other conditions: Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07065539

    GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients

    Not yet reported First Affiliated Hospital, Sun Yat-Sen University 432 participants Est. completion 2027-12 1 site
    Other conditions: Adenomyosis of Uterus, Frozen Embryo Transfer (FET)
    View official trial listing →
  • Not yet recruiting NCT NCT07101159

    Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

    Not yet reported Fujian Cancer Hospital 200 participants Est. completion 2031-12 Stand-alone
    Other conditions: Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT07143682

    Letrozole Step up Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome

    Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 70 participants Est. completion 2024-06-30 1 site Stand-alone
    Other conditions: Polycystic Ovarian Syndrome (PCOS), Infertility
    View official trial listing →
  • Completed NCT NCT07168837

    Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction

    Not yet reported Al-Azhar University 100 participants Est. completion 2024-05-10 1 site
    Other conditions: PCOS (Polycystic Ovary Syndrome)
    View official trial listing →
  • Not yet recruiting NCT NCT07179939

    Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

    Not yet reported Fudan University 288 participants Est. completion 2031-12-30 1 site Stand-alone
    Other conditions: HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT07274709

    Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases

    Shirley Vichy Wang 2495 participants Est. completion 2026-01-01 1 site
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT07379502

    Endometrial Response in Polyendocrine Metabolic Ovarian Syndrome (PMOS) Treated With Letrozole Alone or With Added Estradiol Valerate

    Not yet reported CMH Kharian Medical College 60 participants Est. completion 2026-08-31 1 site Stand-alone
    Other conditions: Polyendocrine Metabolic Ovarian Syndrome (PMOS)
    View official trial listing →
  • Not yet recruiting NCT NCT07394946

    Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.

    Not yet reported Cancer Care Hospital & Research Centre Foundation, Lahore 126 participants Est. completion 2029-07 1 site Stand-alone
    Other conditions: Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07425990

    FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles

    Not yet reported University of Novi Sad 120 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Infertility Female, Frozen Embryo Transfer (FET)
    View official trial listing →
  • Active, not recruiting NCT NCT07448272

    Letrozole 5 mg for 10 Days Versus Letrozole 10 mg for 5 Days for Ovarian Stimulation in PCOS

    Not yet reported Mst.Sumyara Khatun 80 participants Est. completion 2026-10-01 1 site Stand-alone
    Other conditions: PCOS (Polycystic Ovary Syndrome)
    View official trial listing →
  • Completed NCT NCT07513480

    Pretreatment With CPA-EE, Metformin and Myoinositol in PCOS With High AMH

    Not yet reported Mst.Sumyara Khatun 68 participants Est. completion 2026-02-20 1 site Stand-alone
    Other conditions: PCOS
    View official trial listing →
  • Not yet recruiting NCT NCT07527806

    Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

    Not yet reported Peking University Cancer Hospital & Institute 156 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07540611

    Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive

    Not yet reported Indira IVF Hospital Pvt Ltd 860 participants Est. completion 2027-07-17 8 sites Stand-alone
    Other conditions: APHRODITE Group
    View official trial listing →
  • Completed NCT NCT07585396

    Inositol in Letrozol Resistant PCOS Women

    Not yet reported, Not yet reported Kafrelsheikh University 136 participants Est. completion 2026-07-11 1 site
    Other conditions: Polycystic Ovary Syndrome, Infertility
    View official trial listing →
  • Completed NCT NCT07589075

    Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation

    Not yet reported Beni-Suef University 500 participants Est. completion 2025-10-30 1 site Stand-alone
    Other conditions: Induction of Ovulation
    View official trial listing →
  • Not yet recruiting NCT NCT07618923

    Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer

    Not yet reported Tang-Du Hospital 20 participants Est. completion 2029-01 Stand-alone
    Other conditions: Breast Cancer, HR Positive/HER2 Low Breast Cancer
    View official trial listing →
  • Completed NCT NCT07635082

    Extended Letrozole Protocol Versus Letrozole Plus Inositol for Induction of Ovulation in Letrozole Resistant PCOS Women

    Not yet reported Eman Basuni Ebrahim Mowad 200 participants Est. completion 2025-07-01 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome (PCOS) Women, Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT07636317

    Letrozole Plus Misoprostol Versus Misoprostol Only in Induction of Missed Abortion

    Not yet reported Sohag University 400 participants Est. completion 2026-03-01 1 site Stand-alone
    Other conditions: Letrozole, Misoprostol, Induction, Missed Abortion
    View official trial listing →
  • Not yet recruiting NCT NCT07706933

    Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

    Not yet reported Henan Cancer Hospital 456 participants Est. completion 2033-06-30 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07716046

    Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

    Not yet reported Fudan University 240 participants Est. completion 2032-12-31 Stand-alone
    Other conditions: Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer, HR+/HER2+ Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07753655

    The Value of Pretreatment With Letrozole on Induction Time of Medical Evacuation With Misoprostol in Cases of Missed Abortion

    Not yet reported Cairo University 74 participants Est. completion 2027-03-01 Stand-alone
    Other conditions: Letrozole
    View official trial listing →
  • Completed NCT NCT07759518

    Letrozole High Dose (10 mg) Compared to Letrozole Low Dose( 5 mg) for Ovarian Stimulation in Infertile Women With Polycystic Ovary Syndrome

    Not yet reported Mst.Sumyara Khatun 86 participants Est. completion 2026-02-01 1 site Stand-alone
    Other conditions: PCOS
    View official trial listing →
  • Not yet recruiting NCT NCT07767435

    Second Trimester Abortion With Letrozole and Misoprostol Compared to Misoprostol Alone

    Not yet reported, Not yet reported Sohag University 80 participants Est. completion 2027-06-01
    Other conditions: Abortion Induced Complicated, Abortion
    View official trial listing →
  • Not yet recruiting NCT NCT07795424

    Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

    Not yet reported Shengjing Hospital 33 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Breast Cancer, HR Positive, HER2 Positive Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07796880

    Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80 participants Est. completion 2033-03-15 1 site Stand-alone
    Other conditions: Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07801898

    Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer

    Not yet reported The Second Hospital of Anhui Medical University 36 participants Est. completion 2029-03-30 1 site Stand-alone
    Other conditions: Invasive Breast Cancer (Stage I-III)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Letrozole, Letrozole 2.5mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.